Impact of SGLT2 inhibitors on major clinical events and safety outcomes in heart failure patients: a meta-analysis of randomized clinical trials

BACKGROUND: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) significantly reduce the risk of cardiovascular (CV) and renal adverse events in patients with diabetes mellitus, heart failure (HF) and/or chronic kidney disease. We performed a meta-analysis to explore the impact of several different...

Descripción completa

Detalles Bibliográficos
Autores principales: Bazoukis, George, Papadatos, Stamatis S., Thomopoulos, Costas, Tse, Gary, Cheilidis, Stefanos, Tsioufis, Konstantinos, Farmakis, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Science Press 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558745/
https://www.ncbi.nlm.nih.gov/pubmed/34754290
http://dx.doi.org/10.11909/j.issn.1671-5411.2021.10.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558745/
https://www.ncbi.nlm.nih.gov/pubmed/34754290
http://dx.doi.org/10.11909/j.issn.1671-5411.2021.10.003

Ejemplares similares